Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $18.03 USD
Change Today 0.00 / 0.00%
Volume 0.0
SNNUF On Other Exchanges
New York
As of 8:10 PM 07/20/15 All times are local (Market data is delayed by at least 15 minutes).

smith & nephew plc (SNNUF) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/23/14 - $19.25
52 Week Low
10/16/14 - $14.35
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SMITH & NEPHEW PLC (SNNUF)

Related News

No related news articles were found.

smith & nephew plc (SNNUF) Related Businessweek News

No Related Businessweek News Found

smith & nephew plc (SNNUF) Details

Smith & Nephew plc develops, manufactures, markets, and sells medical devices in the advanced surgical devices and advanced wound management sectors worldwide. The company’s Advanced Surgical Devices segment offers orthopedic reconstruction products, including hip and knee implants, as well as ancillary products, such as bone cement and mixing systems used in cemented reconstruction joint surgery. It also provides trauma and extremities products consisting of internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints. In addition, this segment offers arthroscopy enabling technologies for healthcare providers, such as fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources and monitors to assist with visualization inside the joints, radio frequency wands, electromechanical and mechanical blades, and hand instruments for removing damaged tissue; and gynecological instrumentation devices. The company’s Advanced Wound Management segment offers a range of products for the treatment of acute and chronic wounds, including leg, diabetic and pressure ulcers, burns, and post-operative wounds. This segment also provides traditional and single-use negative pressure wound therapy and hydrosurgery systems; and biologics and other bioactive technology products for debridement and dermal repair/regeneration. The company primarily serves the providers of medical and surgical treatments and services. Smith & Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom.

14,242 Employees
Last Reported Date: 03/5/15
Founded in 1856

smith & nephew plc (SNNUF) Top Compensated Officers

Chief Executive Officer, Director, Chairman o...
Total Annual Compensation: $3.2M
Chief Financial Officer, Director and Member ...
Total Annual Compensation: $1.8M
Compensation as of Fiscal Year 2014.

smith & nephew plc (SNNUF) Key Developments

Morgan Stanley To Reportedly Advise On Sale Of Cremer

Tarpon Investimentos S.A. (BOVESPA:TRPN3) has reportedly hired Morgan Stanley & Co to explore a sale of Cremer SA (BOVESPA:CREM3). Tarpon Investimentos owning 96% stake in Cremer has launched a formal sale process aimed especially at foreign bidders, said the sources, who requested anonymity since the matter is private. Morgan Stanley & Co had already offered the company to a group of investment funds and possible strategic buyers such as Smith & Nephew plc (LSE:SN.), two of the sources noted. They said São Paulo-based Tarpon wants at least $190 million for Cremer.

Smith & Nephew plc Announces Consolidated Sales Results for the First Quarter Ended March 28, 2015; Provides Earnings Guidance for the Full Year 2015

Smith & Nephew plc announced consolidated sales results for the first quarter ended March 28, 2015. For the quarter, the company reported consolidated revenue of $1,104 million against $1,073 million, last year. The company provided earnings guidance for the full year 2015. The full year outlook for the Group remains unchanged and continues to expect to deliver higher underlying revenue growth in 2015 than in 2014 and an improvement in trading profit margin. The company expects the phasing of revenue and profit to be more pronounced in 2015 than 2014, with profitability in the second half being significantly stronger than the first.

Smith & Nephew plc Announces Final Dividend for the Year Ended 31 December 2014, Payable on 6 May 2015

Smith & Nephew plc announced a final dividend of 18.6 US cents per ordinary share in respect of the year ended 31 December 2014 will be paid on 6 May 2015 to shareholders whose names appeared on the register at the close of business on 17 April 2015. Those shareholders whose address on the Register is in the UK, and those who have validly elected to receive sterling dividends, will receive a dividend of 12.34 pence per share.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNNUF:US $18.03 USD 0.00

SNNUF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CR Bard Inc $192.95 USD +2.81
Edwards Lifesciences Corp $155.80 USD +3.08
Olympus Corp ¥4,715 JPY +15.00
St Jude Medical Inc $74.19 USD +1.01
Zimmer Biomet Holdings Inc $106.50 USD +0.72
View Industry Companies

Industry Analysis


Industry Average

Valuation SNNUF Industry Range
Price/Earnings 31.3x
Price/Sales 3.4x
Price/Book 3.9x
Price/Cash Flow 31.2x
TEV/Sales 3.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SMITH & NEPHEW PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at